Anivamersen-pegnivacogin

Drug Profile

Anivamersen-pegnivacogin

Alternative Names: Anivamersen; Pegnivacogin; Pegnivacogin/anivamersen; RB 006; RB 006/RB 007; RB 007; REG-1; REG-2; Revolixys

Latest Information Update: 14 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Archemix Corporation
  • Developer Tobira Therapeutics
  • Class Anticoagulants; Antidotes; Antithrombotics; Nucleotide aptamers; Oligonucleotides
  • Mechanism of Action Factor IXa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Venous thrombosis

Most Recent Events

  • 01 Nov 2016 Tobira Therapeutics has been acquired by Allergan
  • 05 May 2015 Regado Biosciences has merged with Tobira Therapeutics and renamed Tobira Therapeutics
  • 25 Aug 2014 Regado Biosciences permanently terminates enrolment in the phase III REGULATE-PCI trial (NCT01848106)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top